Skip to main content

Table 3 FM score at baseline(W0) and W24

From: Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study

ID

W-24

W0

W24

W24-W0

W0-W-24

1

24.0

44.0

42.0

−2.0

20.0

2

63.0

72.0

61.0

−11.0

9.0

3

55.0

75.0

66.0

−9.0

20.0

4

8.0

12.0

9.0

−3.0

4.0

5

40.0

50.0

44.0

−6.0

10.0

6

90.0

102.0

94.0

−8.0

12.0

7

51.0

71.0

75.0

4.0

20.0

8

18.0

18.0

16.0

−2.0

0.0

9

15.0

31.0

35.0

4.0

16.0

10

65.0

60.0

61.0

1.0

−5.0

11

6.0

24.0

15.0

−9.0

18.0

12

60.0

70.0

76.5

6.5

10.0

13

46.0

49.0

56.0

7.0

3.0

14

36.0

51.0

74.0

23.0

15.0

15

23.0

49.0

67.0

18.0

26.0

M ± SD

40.0 ± 24.3

51.9 ± 24.3

52.8 ± 25.3

/

/

t/Z

 

0.353a

2.643b

P

 

0.729a

0.008b

  1. “/” means no statistical analysis was performed
  2. “a” means difference between W24 and W0, Paired t test was performed
  3. “b” means difference of the rate of increase before and after treatment, Wilcoxon rank sum test was performed